BACKGROUND: Chronic graft-versus-host disease (cGVHD) is a major complication after allogeneic stem cell transplantation with an adverse effect on both mortality and morbidity. In 2005, the National Institute of Health proposed new criteria for diagnosis and classification of chronic graft-versus-host disease for clinical trials. New sub-categories were recognized such as late onset acute graft-versus-host disease and overlap syndrome. DESIGN AND METHODS: We evaluated the prognostic impact of the new sub-categories as well as the clinical scoring system proposed by the National Institute of Health in a retrospective, multicenter study of 820 patients undergoing allogeneic stem cell transplantation between 2000 and 2006 at 3 different institutions. Patients were retrospectively categorized according to the National Institute of Health criteria from patients' medical histories. RESULTS: As far as the new sub-categories are concerned, in univariate analysis diagnosis of overlap syndrome adversely affected the outcome. Also, the number of organs involved for a cut-off value of 4 significantly influenced both cGVHD related mortality and survival. In multivariate analysis, in addition to NIH score, platelet count and performance score at the time of cGVHD diagnosis, plus gut involvement, significantly influenced outcome. These 3 variables allowed us to develop a simple score system which identifies 4 subgroups of patients with 84%, 64%, 43% and 0% overall survival at five years after cGVHD diagnosis (score 0: HR=15.96 (95% CI: 6.85-37.17), P<0.001; score 1: HR=5.47 (95% CI: 2.6-11.5), P<0.001; score 2: HR=2.8 (95% CI: 1.32-5.93), P=0.007). CONCLUSIONS: In summary, we have identified a powerful and simple tool to discriminate different subgroups of patients in terms of chronic graft-versus-host disease related mortality and survival.
BACKGROUND: Chronic graft-versus-host disease (cGVHD) is a major complication after allogeneic stem cell transplantation with an adverse effect on both mortality and morbidity. In 2005, the National Institute of Health proposed new criteria for diagnosis and classification of chronic graft-versus-host disease for clinical trials. New sub-categories were recognized such as late onset acute graft-versus-host disease and overlap syndrome. DESIGN AND METHODS: We evaluated the prognostic impact of the new sub-categories as well as the clinical scoring system proposed by the National Institute of Health in a retrospective, multicenter study of 820 patients undergoing allogeneic stem cell transplantation between 2000 and 2006 at 3 different institutions. Patients were retrospectively categorized according to the National Institute of Health criteria from patients' medical histories. RESULTS: As far as the new sub-categories are concerned, in univariate analysis diagnosis of overlap syndrome adversely affected the outcome. Also, the number of organs involved for a cut-off value of 4 significantly influenced both cGVHD related mortality and survival. In multivariate analysis, in addition to NIH score, platelet count and performance score at the time of cGVHD diagnosis, plus gut involvement, significantly influenced outcome. These 3 variables allowed us to develop a simple score system which identifies 4 subgroups of patients with 84%, 64%, 43% and 0% overall survival at five years after cGVHD diagnosis (score 0: HR=15.96 (95% CI: 6.85-37.17), P<0.001; score 1: HR=5.47 (95% CI: 2.6-11.5), P<0.001; score 2: HR=2.8 (95% CI: 1.32-5.93), P=0.007). CONCLUSIONS: In summary, we have identified a powerful and simple tool to discriminate different subgroups of patients in terms of chronic graft-versus-host disease related mortality and survival.
Authors: Sally Arai; Madan Jagasia; Barry Storer; Xiaoyu Chai; Joseph Pidala; Corey Cutler; Mukta Arora; Daniel J Weisdorf; Mary E D Flowers; Paul J Martin; Jeanne Palmer; David Jacobsohn; Steven Z Pavletic; Georgia B Vogelsang; Stephanie J Lee Journal: Blood Date: 2011-07-26 Impact factor: 22.113
Authors: K Atkinson; M M Horowitz; R P Gale; D W van Bekkum; E Gluckman; R A Good; N Jacobsen; H J Kolb; A A Rimm; O Ringdén Journal: Blood Date: 1990-06-15 Impact factor: 22.113
Authors: S Carlens; O Ringdén; M Remberger; B Lönnqvist; H Hägglund; S Klaesson; J Mattsson; B M Svahn; J Winiarski; P Ljungman; J Aschan Journal: Bone Marrow Transplant Date: 1998-10 Impact factor: 5.483
Authors: M M Horowitz; R P Gale; P M Sondel; J M Goldman; J Kersey; H J Kolb; A A Rimm; O Ringdén; C Rozman; B Speck Journal: Blood Date: 1990-02-01 Impact factor: 22.113
Authors: Stephanie J Lee; John P Klein; A John Barrett; Olle Ringden; Joseph H Antin; Jean-Yves Cahn; Matthew H Carabasi; Robert Peter Gale; Sergio Giralt; Gregory A Hale; Osman Ilhan; Philip L McCarthy; Gerard Socie; Leo F Verdonck; Daniel J Weisdorf; Mary M Horowitz Journal: Blood Date: 2002-07-15 Impact factor: 22.113
Authors: H M Shulman; K M Sullivan; P L Weiden; G B McDonald; G E Striker; G E Sale; R Hackman; M S Tsoi; R Storb; E D Thomas Journal: Am J Med Date: 1980-08 Impact factor: 4.965
Authors: T Bat; S M Steinberg; R Childs; K R Calvo; A J Barrett; M Battiwalla; K Baird; D Zhang; D Pulanic; C E Dunbar; S Z Pavletic Journal: Bone Marrow Transplant Date: 2013-07-08 Impact factor: 5.483
Authors: Djamilia Dierov; Nicholas Webb; Samira Fatmi; Chamberlain Nwanne; Cristi Ciolino; Kara Mosesso; Jimmy Nieves; Miguel-Angel Perales; Susan E Prockop; Doris M Ponce Journal: Adv Cell Gene Ther Date: 2019-05-02
Authors: Teresa Lopes Ramos; Estefanía García-Guerrero; Teresa Caballero-Velázquez; Alfonso Rodríguez-Gil; Rocío Caracuel-García; Melanie Nufer; María José Robles-Frías; María Victoria Barbado; José A Pérez-Simón Journal: Bone Marrow Transplant Date: 2021-09-23 Impact factor: 5.483
Authors: Gabriel Afram; Jose Antonio Pérez Simón; Mats Remberger; Teresa Caballero-Velázquez; Rodrigo Martino; Jose Luis Piñana; Olle Ringden; Albert Esquirol; Lucia Lopez-Corral; Irene Garcia; Oriana López-Godino; Jordi Sierra; Dolores Caballero; Per Ljungman; Lourdes Vazquez; Hans Hägglund Journal: Med Oncol Date: 2018-04-25 Impact factor: 3.064